Indonesia Approves COVID-19 Vaccine from Zhifei’s Chinese Unit, Health News, ET HealthWorld
BPOM chief Penny Lukito said the recombinant protein vaccine, given three times in three months, had an efficacy rate of around 81%, with an efficacy of 77.47% against the Delta variant, which was less than that of the other variants, she said.
Trials of the vaccine, Zifivax, have been conducted in China, Uzbekistan, Pakistan, Ecuador and Indonesia, involving 28,000 people, with efficacy based on any degree of severity.
Indonesia has also approved the use of Sinovac, Sinopharm and CanSino vaccines.
Once the epicenter of COVID-19 in Asia, Indonesia has vaccinated a fifth of its population of around 270 million people.
It has recorded more than 4.2 million cases of coronavirus and 142,000 total deaths, but average daily infections have declined significantly since the peak of its crisis in July.
Mahendra Suhardono, head of the Jakarta biopharmaceutical industry, which is in partnership with Zhifei, said Zifivax injections could be produced in Indonesia this year.
Zhifei and his unit, Anhui Zhifei Longcom Biopharmaceutical, did not immediately respond to requests for comment.